GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Regencell Bioscience Holdings Ltd (NAS:RGC) » Definitions » EBITDA Margin %

Regencell Bioscience Holdings (Regencell Bioscience Holdings) EBITDA Margin % : 0.00% (As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Regencell Bioscience Holdings EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Regencell Bioscience Holdings's EBITDA for the six months ended in Jun. 2023 was $-2.84 Mil. Regencell Bioscience Holdings's Revenue for the six months ended in Jun. 2023 was $0.00 Mil. Therefore, Regencell Bioscience Holdings's EBITDA margin for the quarter that ended in Jun. 2023 was 0.00%.


Regencell Bioscience Holdings EBITDA Margin % Historical Data

The historical data trend for Regencell Bioscience Holdings's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regencell Bioscience Holdings EBITDA Margin % Chart

Regencell Bioscience Holdings Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23
EBITDA Margin %
- - - - -

Regencell Bioscience Holdings Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Regencell Bioscience Holdings's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Regencell Bioscience Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regencell Bioscience Holdings's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Regencell Bioscience Holdings's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Regencell Bioscience Holdings's EBITDA Margin % falls into.



Regencell Bioscience Holdings EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Regencell Bioscience Holdings's EBITDA Margin % for the fiscal year that ended in Jun. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Jun. 2023 )/Revenue (A: Jun. 2023 )
=-5.504/0
= %

Regencell Bioscience Holdings's EBITDA Margin % for the quarter that ended in Jun. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2023 )/Revenue (Q: Jun. 2023 )
=-2.844/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regencell Bioscience Holdings  (NAS:RGC) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Regencell Bioscience Holdings EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Regencell Bioscience Holdings's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Regencell Bioscience Holdings (Regencell Bioscience Holdings) Business Description

Traded in Other Exchanges
N/A
Address
29 Leighton Road, 9/F Chinachem Leighton Plaza, Causeway Bay, Hong Kong, HKG
Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional Chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.

Regencell Bioscience Holdings (Regencell Bioscience Holdings) Headlines

From GuruFocus